The impact of micronized progesterone on breast cancer risk: a systematic review.
Climacteric. 2018.
PMID: 29384406
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1988 | 1 |
| 1990 | 2 |
| 1999 | 1 |
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 4 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 4 |
Search Results
62 results
Results by year
Citations
2
articles
found by citation matching
Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
Breast Cancer Res Treat. 2007.
PMID: 16841178
Search results
Page 1
The impact of micronized progesterone on breast cancer risk: a systematic review.
Climacteric. 2018 Apr;21(2):111-122. doi: 10.1080/13697137.2017.1421925. Epub 2018 Jan 31.
Climacteric. 2018.
PMID: 29384406
Free article.
The debate on bioidentical hormones including micronized progesterone has increased in recent years. Based on a systematic literature review on the impact of menopausal hormone therapy (MHT) containing micronized progesterone on the mammary gland, an i …
The debate on bioidentical hormones including micronized progesterone has increased in recent years. Based on a systematic lit …
Menopausal hormone therapy and breast cancer risk.
Best Pract Res Clin Endocrinol Metab. 2021 Dec;35(6):101577. doi: 10.1016/j.beem.2021.101577. Epub 2021 Sep 10.
Best Pract Res Clin Endocrinol Metab. 2021.
PMID: 34535397
Review.
In most women the 5-year-breast cancer risk is low (<3%) and MHT is a safe option. MHT should be prescribed with caution in women who have an intermediate risk (3-6%) and should not be prescribed in those who have a high risk of breast …
In most women the 5-year-breast cancer risk is low (<3%) and MHT is a safe option. MHT should be prescribed with cau …
Menopausal Hormone Therapy Formulation and Breast Cancer Risk.
Obstet Gynecol. 2022 Jun 1;139(6):1103-1110. doi: 10.1097/AOG.0000000000004723. Epub 2022 May 3.
Obstet Gynecol. 2022.
PMID: 35675607
OBJECTIVE: To evaluate whether the increased risk of breast cancer is dependent on the formulation of menopausal hormone therapy (HT) used. ...Progestogens appeared to be differentially associated with breast cancer (micronized progest …
OBJECTIVE: To evaluate whether the increased risk of breast cancer is dependent on the formulation of menopausal hormon …
Diagnostic and therapeutic use of oral micronized progesterone in endocrinology.
Rev Endocr Metab Disord. 2024 Aug;25(4):751-772. doi: 10.1007/s11154-024-09882-0. Epub 2024 Apr 23.
Rev Endocr Metab Disord. 2024.
PMID: 38652231
Free PMC article.
Review.
In addition, it exerts numerous effects on other endocrine systems. Micronized progesterone (MP) is natural progesterone with increased bioavailability, due to its pharmacotechnical micronized structure, which makes it an attractive diagnostic and ther …
In addition, it exerts numerous effects on other endocrine systems. Micronized progesterone (MP) is natural progesterone …
Menopausal hormone treatment and breast cancer.
Lancet Diabetes Endocrinol. 2026 Mar;14(3):259-274. doi: 10.1016/S2213-8587(25)00394-8. Epub 2026 Jan 28.
Lancet Diabetes Endocrinol. 2026.
PMID: 41619758
Review.
Oestrogen only therapy in women who have undergone hysterectomy appears associated with a lower risk of breast cancer than combined oestrogen and progestogen MHT. Micronised progesterone and dydrogesterone seem associated with a lower risk …
Oestrogen only therapy in women who have undergone hysterectomy appears associated with a lower risk of breast cancer t …
Progestogens in Menopausal Hormone Therapy: A Double-Edged Sword.
Semin Reprod Med. 2025 Jun;43(2):145-153. doi: 10.1055/s-0045-1809186. Epub 2025 May 16.
Semin Reprod Med. 2025.
PMID: 40378875
Review.
Progestogen addition is accompanied with significant elevations in breast cancer risk, the largest drawback of progestogen use, and dydrogesterone, micronized progesterone, and a levonorgestrel intrauterine device may be safest in this regard. P …
Progestogen addition is accompanied with significant elevations in breast cancer risk, the largest drawback of progesto …
Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens Français (CNGOF) and Groupe d'Etude sur la Ménopause et le Vieillissement (GEMVi) Clinical Practice Guidelines.
Maturitas. 2022 Sep;163:62-81. doi: 10.1016/j.maturitas.2022.05.008. Epub 2022 Jun 9.
Maturitas. 2022.
PMID: 35717745
Free article.
Review.
SUMMARY RECOMMENDATIONS: The beginning of menopause is an ideal time for each woman to evaluate her health status by assessing her bone, cardiovascular, and cancer-related risk factors that may be amplified by postmenopausal estrogen deficiency and by reviewing her …
SUMMARY RECOMMENDATIONS: The beginning of menopause is an ideal time for each woman to evaluate her health status by assessing her bone, car …
Progesterone--promoter or inhibitor of breast cancer.
Climacteric. 2013 Aug;16 Suppl 1:54-68. doi: 10.3109/13697137.2013.768806. Epub 2013 Feb 20.
Climacteric. 2013.
PMID: 23336704
Review.
Based on the results of a French cohort of postmenopausal women, it has been claimed that micronized progesterone does not enhance breast cancer risk. The impact of reproductive factors on breast cancer risk and a high preva …
Based on the results of a French cohort of postmenopausal women, it has been claimed that micronized progesterone does not enh …
Progesterone and endometrial cancer.
Best Pract Res Clin Obstet Gynaecol. 2020 Nov;69:95-107. doi: 10.1016/j.bpobgyn.2020.05.003. Epub 2020 Jun 9.
Best Pract Res Clin Obstet Gynaecol. 2020.
PMID: 32732107
Review.
It is well established that unopposed estrogen, either endogenous or therapeutic, can induce endometrial hyperplasia and potentially endometrial cancer (EC). Anovulatory cycles, obesity, and insulin resistance are major risk factors for EC. ...Whereas, recent epidem …
It is well established that unopposed estrogen, either endogenous or therapeutic, can induce endometrial hyperplasia and potentially endomet …
Is breast cancer risk the same for all progestogens?
Arch Gynecol Obstet. 2014 Aug;290(2):207-9. doi: 10.1007/s00404-014-3270-0.
Arch Gynecol Obstet. 2014.
PMID: 24838289
Free article.
The population-based case-control study CECILE investigated the impact of various menopausal hormone therapy (MHT) products on breast cancer (BC) risk in 1,555 postmenopausal women [1]. The case group (n = 739) included incident cases of in situ (!) ...EPT wa …
The population-based case-control study CECILE investigated the impact of various menopausal hormone therapy (MHT) products on breast …
Cite